[Federal Register Volume 62, Number 112 (Wednesday, June 11, 1997)]
[Notices]
[Pages 31835-31836]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-15299]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for U.S. companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Methods for Detecting Cervical Cancer
T Ried et al. (NHGRI)
U.S. Patent Serial No. 08/781,424 filed 10 Jan 97
Licensing Contact: Mary Savagner, 301/496-7735 ext. 205
Last year, nearly 16,000 women in the United States were diagnosed
with invasive cervical carcinoma and nearly 5,000 women died from the
disease. While the widespread promotion and use of the Pap smear has
contributed to the reduced mortality rate associated with the disease
over the last 30 years, there is still a need for improvement and
optimization of the screening process. Despite tremendous efforts, the
automated analysis of cervical PAP smears based on cytopathological
stains has not been achieved. Also, cytopathological analyses reveal
insufficient information to predict disease progression.
This invention provides a method of detecting the presence of
invasive cervical carcinoma by detecting in a cervical cell taken from
a patient the presence of a chromosomal aberration indicating the
presence of invasive cervical carcinoma. The invention also provides a
method of diagnosing advanced-stage cervical carcinoma in a patient as
well as a method of classifying the progression of dysplastic cervical
cells from non-invasive to invasive cervical carcinoma. In addition,
the invention provides kits comprising nucleic acids that specifically
hybridize in chromosome 3q and specifically hybridize to another
chromosome, and to compositions comprising nucleic acids. (portfolio:
Cancer--Diagnostics, in vitro, other)
Chimeric Nucleic Acid Sequences Encoding attenuated Hepatitis A Viruses
and the Use of These Sequences and Viruses as Vaccines
SU Emerson, SA Harmon, E Ehrenfeld, DF Summers (NIAID)
Serial No. 08/547,482 filed 24 Oct 95
Licensing Contact: Gloria Richmond, 301/496-7056 ext. 268
This invention is directed to chimeric hepatitis A viruses,
containing mutations in the 2A gene, which will be used as the basis
for an attenuated vaccine for humans. The mutations in the 2A gene are
unusual because they are not naturally occurring mutations but were
engineered into an infectious cDNA clone. These mutations in 2A are
able to decrease pathology substantially and offer the opportunity of
constructing a virus that will induce effective immunity without
causing disease. Sales of the inactivated vaccine in Europe have
demonstrated the commercial importance of a vaccine for hepatitis A. An
attenuated vaccine would be more economical and easier to administer.
(portfolio: Infectious Diseases--Vaccines, viral, non-AIDS)
Vaccine for Dengue Virus
C-J Lai, M Bray, AG Pletnev, R Men, Y-M Zhang, KH Eckels (NIAID)
Serial No. 08/250,802 filed 27 May 94
Licensing Contact: Gloria H. Richmond, 301/496-7056 ext 268
The claimed invention relates to recombinant modified or viable
chimeric dengue viruses for use as vaccines against dengue and other
flavivirus disease, including tick-borne encephalitis. Dengue is a
mosquito-transmitted viral disease which occurs in tropical and
subtropical regions throughout the world. Inactivated whole dengue
virus vaccines have been shown to be insufficiently immunogenic and
live dengue virus vaccines prepared by serial passage in cell culture
have not been shown to be consistently attenuated. A dengue vaccine is
still not available. The present invention represents a technical
breakthrough, which provides new approaches to dengue vaccines by
construction of chimeric dengue viruses of all four serotypes and
strategic modification to produce attentuated virus strains. Several
fields of use remain available for licensing. (portfolio: Infectious
Diseases--Vaccines, viral, non-AIDS)
Parvovirus B19 Receptor and Parvovirus B19 Detection
N Young, K Brown (NHLBI)
Serial No. 08/034,132 filed 22 Mar 93; U.S. Patent 5,449,608 issued 12
Sep 95
Licensing Contact: Gloria H. Richmond, 301/496-7056 ext 268
The claimed invention provides a method of detecting the presence
of a parvovirus in a sample. Parvoviruses infect animals and man. In
man, the only known pathogenic member of this family is parvovirus B19.
The inventors have identified the parvovirus B19 receptor which
provides for a method to diagnose, prevent, and treat parvovirus
infection utilizing the binding affinity for the receptor. (portfolio:
Infectious
[[Page 31836]]
Diseases--diagnostics, viral, non-AIDS; Infectious Diseases--
Therapeutics, anti-viral, non-AIDS)
Dated: May 30, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-15299 Filed 6-10-97; 8:45 am]
BILLING CODE 4140-01-M
